Conditions and areas
Area by area: where research and clinical practice in Japan stand for joints, diabetes, Parkinson’s disease, premature ovarian insufficiency, osteonecrosis of the femoral head and hair loss, and what to ask before you go. Information only; suitability is for a doctor to decide.
01What this topic covers
- Joints and sports injuries
- Diabetes
- Parkinson’s disease
- Premature ovarian insufficiency
- Osteonecrosis of the femoral head
- Hair loss
02Which class it generally falls into in Japan
- iPS cells, ES cells and similar: generally Class I (high risk).
- The patient’s own somatic stem cells (e.g. adipose-derived stem cells): generally Class II (medium risk).
- Somatic cell processing without stem cells (e.g. immune cell therapy): generally Class III (low risk).
- PRP depends on how it is used: injection into a joint or other “non-homologous use” is Class II (medium risk); dental and similar uses are mostly Class III.
This is how treatments generally map; the class of a specific treatment is whatever the clinic’s submitted plan states.
Source: Ministry of Health, Labour and Welfare (MHLW), "再生医療・細胞医療・遺伝子治療について" (Regenerative, cell and gene therapy); MHLW division notice, risk-classification chart; checked 2026-11
03Guides in this topic
Conditions and areasStem Cell and PRP Treatments for Hair Loss: Evidence and LimitsWhat the evidence says about PRP and stem cell treatments for pattern hair loss, how Japan's guideline grades them, and how Japan regulates them for patients.
Conditions and areasStem Cell Therapy for Back Pain and Disc Problems: What the Research ShowsWhat trials of stem cell injections for degenerated discs and chronic low back pain found, how strong the evidence is, and how Japan and the FDA regulate it.
Conditions and areasStem Cell Therapy for Diabetes: How Far the Research Has ComeStem cell-derived islets for type 1 diabetes are in human trials in Japan, the US and China. What the results show, what is approved, and what clinics offer.
Conditions and areasStem Cell Therapy for Knees: Research on Osteoarthritis and Meniscus TearsStem cell injections for knee osteoarthritis and meniscus tears are still research. How Japan classifies them, what is approved and how FDA options compare.
Conditions and areasStem Cell Therapy for Parkinson's Disease: Where Japan's iPS Cell Research StandsJapan granted conditional approval to Amchepry, an iPS cell product for Parkinson's, in 2026. What the trial showed, how it is supplied, and what it is not.